Cytokeratin 5 and cytokeratin 20 inversely correlate with tumour grading in Ta non-muscle-invasive bladder cancer.
CK20
CK5
GATA3
basal
immunohistochemistry
luminal
non-muscle-invasive bladder cancer
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
24
04
2021
received:
15
02
2021
accepted:
13
05
2021
pubmed:
30
6
2021
medline:
19
2
2022
entrez:
29
6
2021
Statut:
ppublish
Résumé
Cytokeratin 5 is a marker of basal molecular subtypes of muscle-invasive bladder cancer (MIBC), which correlates with worse overall survival compared to luminal subtypes. Our observations have not confirmed CK5 as a marker of high-grade (HG) disease in Ta non-muscle-invasive bladder cancer (NMIBC). Therefore, to understand the basal-luminal immunohistochemistry profile in Ta NMIBC, we performed immunohistochemistry for CK5, P40, P63 (basal), GATA3 and CK20 (luminal) and studied the correlation with HG and clinical outcome in 109 patients with Ta NMIBC. HG and low-grade (LG) diseases were scored in each patient. Four different CK5 patterns were evaluated: absent (median 41.3%), normal (72.5%), rising (84.4%) and full thickness (23.9%). The median percentage of GATA3 was 100%. HG disease and CK5 expression and rising CK5 pattern had a significant inverse correlation, whereas HG disease and CK20 expression had a significant positive correlation. We also found a significant inverse correlation between CK5 expression and CK20 expression. Quantitative PCR confirmed that the presence of CK5 correlated with up-regulation of CK5 RNA. None of the markers could differentiate patients with regard to clinical outcome. Our results suggest a role for CK5 and CK20 in differentiating between LG and HG disease in Ta NMIBC.
Identifiants
pubmed: 34184816
doi: 10.1111/jcmm.16712
pmc: PMC8358875
doi:
Substances chimiques
Biomarkers, Tumor
0
KRT20 protein, human
0
KRT5 protein, human
0
Keratin-20
0
Keratin-5
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7890-7900Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Am J Surg Pathol. 2007 May;31(5):673-80
pubmed: 17460449
J Pathol. 2017 May;242(1):113-125
pubmed: 28195647
Cancer Cell. 2014 Feb 10;25(2):152-65
pubmed: 24525232
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Virchows Arch. 2017 Mar;470(3):267-274
pubmed: 28074276
J Cancer Res Clin Oncol. 2019 Dec;145(12):3075-3087
pubmed: 31595333
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Eur Urol. 2017 Sep;72(3):354-365
pubmed: 28365159
J Transl Med. 2020 Aug 5;18(1):303
pubmed: 32758253
J Pathol. 2019 Nov;249(3):308-318
pubmed: 31232464
EBioMedicine. 2016 Oct;12:105-117
pubmed: 27612592
Eur Urol. 2014 Oct;66(4):609-10
pubmed: 24877661
Sci Rep. 2015 Jun 08;5:10957
pubmed: 26051783
Cancer Cell. 2016 Jul 11;30(1):27-42
pubmed: 27321955
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Virchows Arch. 2017 Aug;471(2):271-280
pubmed: 28429075
Bladder Cancer. 2016 Jan 7;2(1):37-47
pubmed: 27376123
Eur Urol. 2020 Apr;77(4):420-433
pubmed: 31563503
Eur Urol. 2015 Nov;68(5):824-32; discussion 835-6
pubmed: 25770486
Eur Urol. 2008 Jan;53(1):146-52
pubmed: 17624657
Am J Pathol. 2013 Sep;183(3):681-91
pubmed: 23827819
PLoS One. 2017 Jun 20;12(6):e0179602
pubmed: 28632777
J Cell Mol Med. 2021 Aug;25(16):7890-7900
pubmed: 34184816
Histopathology. 2019 Feb;74(3):483-493
pubmed: 30286252
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell Mol Life Sci. 2018 Mar;75(6):965-973
pubmed: 28975366